Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

8.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

419
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

378
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
378

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and radiographic outcomes of supramalleolar osteotomy with or without fibular osteotomy in the treatment of varus ankle osteoarthritis: a single-center retrospective study.

BMC musculoskeletal disorders·2026
Same author

Molecular Symphony of Sympathetic Acceleration: Reframing the Pacemaker Paradigm.

Circulation research·2026
Same author

Loss-of-Function Mutation RyR2-A4860G Confers an Arrhythmia Phenotype in Mice Inconsistent With Calcium Release Deficiency Syndrome.

Circulation. Arrhythmia and electrophysiology·2025
Same author

Conserved region amino acid mutations in Calcin: Altering the RyR structural-functional relationship.

Toxicon : official journal of the International Society on Toxinology·2025
Same author

Critical length screening enables 19% efficiency in thick-film organic solar cells.

Nature communications·2025
Same author

Development of a Highly Specific Immunoassay for Residual Venom Detection of the Toxic Jellyfish <i>Nemopilema nomurai</i>.

Toxics·2025

Related Experiment Video

Updated: Jan 10, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.5K

OpiCa1 Modulates Cardiomyocyte Viability Through PI3K/Akt Inhibition with Minimal Systemic Impact Beyond RyR

Xiaofen Ma1,2, Xiaoyu Hua2,3,4, Xiao Peng2,3,4

  • 1Xinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Engineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, School of Pharmacy, Xinjiang Medical University, Ürümqi 830000, China.

Toxins
|November 26, 2025
PubMed
Summary
This summary is machine-generated.

Opicalcin1 (OpiCa1) reduces cardiac cell viability and promotes apoptosis by inhibiting the PI3K/Akt pathway. Despite this, high doses show minimal systemic toxicity, supporting calcin-based cardiac disease therapies.

Keywords:
Ca2+OpiCa1PI3K/Akt signalingapoptosisryanodine receptortranscriptomics

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.1K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Related Experiment Videos

Last Updated: Jan 10, 2026

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.5K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.1K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.5K

Area of Science:

  • Cardiovascular Biology
  • Molecular Pharmacology
  • Cellular Toxicology

Background:

  • Calcins are novel peptide ligands for ryanodine receptors (RyRs) with therapeutic potential for cardiac diseases.
  • The non-RyR-mediated biological effects and mechanisms of calcins are largely unknown.

Purpose of the Study:

  • To investigate the effects of Opicalcin1 (OpiCa1), a potent calcin, on cardiomyocyte viability and explore its underlying mechanisms.
  • To assess the in vivo systemic toxicity of OpiCa1.

Main Methods:

  • Utilized H9c2 cardiomyocytes for in vitro studies.
  • Employed transcriptomics and Western blot analyses to identify molecular pathways.
  • Conducted acute and chronic in vivo studies in animal models.

Main Results:

  • OpiCa1 reduced cytosolic Ca2+ but decreased H9c2 cell viability and induced apoptosis.
  • Suppression of the PI3K/Akt pathway was identified as the mechanism for OpiCa1's cellular effects.
  • High-dose OpiCa1 (≥50 mg/kg i.v.) showed minimal impact on body weight, histopathology, and organ indices, with subtle serum indicator alterations.

Conclusions:

  • OpiCa1 modulates cardiomyocyte viability via PI3K/Akt inhibition.
  • OpiCa1 exhibits minimal systemic toxicity in vivo.
  • Findings provide insights into non-RyR actions of calcins and toxicological data for calcin-based cardiac therapies.